Telix Pharmaceuticals Limited (TLX,TLX.AX) announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TLX101-Px (Pixclara, Floretyrosine F 18 or 18F-FET). This investigational PET imaging agent is intended to help differentiate recurrent or progressive glioma (a type of brain cancer) from treatment-related changes in both adult and pediatric patients.
The resubmission includes additional data and statistical analyses requested by the FDA. Following a Type A meeting and ongoing consultation, Telix believes the new information, combined with the original dataset, adequately addresses the FDA's Complete Response Letter.
TLX101-Px has been granted Orphan Drug and Fast Track designations, underscoring its potential to address a significant unmet medical need. Although 18F-FET PET imaging is already recognized in international clinical practice guidelines for glioma imaging, there is currently no FDA-approved targeted amino acid PET agent available in the U.S. for adult or pediatric brain cancer imaging.
TLX.AX is currently trading at A$11.01, down A$0.28 or 2.48%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.